Previous studies with indisulam, conducted by Lu et al., have demonstrated that the splicing modulation induced by RBM39 degradation generated neoantigens that could be recognized by immune cells, triggering an anti-tumor T-cell response and the inhibition of tumor growth [28]. Here, RBM39 is linked to neoplasm.